

Cuban experience with local production of medicines, technology transfer and improving access to health



 Intellectual
Property and Trade

 R&D
Innovation

 Technology
Transfer

 Improving Access

 Financing

 Monitoring and
Reporting



European
Commission



Pan American
Health
Organization



World Health
Organization

Cuban experience with local production of medicines, technology transfer and improving access to health



European
Commission



Pan American
Health
Organization



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Cuban experience with local production of medicines, technology transfer and improving access to health.

1. Drugs, Essential. 2. Technology Transfer. 3. Delivery of Health Care. 4. National Health Programs. 5. Case Reports. 6. Cuba. I. World Health Organization. II. Pan American Health Organization. III. European Commission.

ISBN 978 92 4 150971 8

(NLM classification: QV 704)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

Editing and design by Inis Communication – www.iniscommunication.com

Photo: WHO/PAHO/Sabin Institute/Flickr

Contents

Preface	1
Acknowledgements	2
Executive summary	3
Abbreviations	5
Cuba's Experience in Domestic Production of Medicines, Technology Transfer and Improvements in Access to Health Care	6
1. Introduction	8
1.1 <i>Objective and scope</i>	8
1.2 <i>Methodology</i>	8
2. Political context	10
2.1 <i>Education sector</i>	10
2.2 <i>Health sector</i>	11
2.3 <i>Maintenance, development and coherence of policies designed to ensure access to health technologies</i>	13
3. Human resources policy	15
3.1 <i>Background</i>	15
3.2 <i>Human resources</i>	16
3.3 <i>Cuban higher education</i>	16
3.4 <i>Human resources and the Cuban biopharmaceutical industry</i>	18
4. Technology policy	20
4.1 <i>National Center for Scientific Research (CNIC)</i>	22
4.2 <i>Biological Research Center (CIB)</i>	22
4.3 <i>Genetic Engineering and Biotechnology Center (CIGB)</i>	22
4.4 <i>Immunoassay Center (CIE)</i>	23
4.5 <i>Finlay Institute</i>	23
4.6 <i>National Bioproducts Center (BIOCEN)</i>	24
4.7 <i>Molecular Immunology Center (CIM)</i>	24
4.8 <i>Cuban Neurosciences Center (CNEURO)</i>	25
4.9 <i>National Center for Production of Laboratory Animals (CENPALAB)</i>	26
5. Industrial policy	27
5.1 <i>Creation of BioCubaFarma</i>	27
5.2 <i>Funding of the Cuban biopharmaceutical industry</i>	28
5.3 <i>Business modalities of the biopharmaceutical industry</i>	28
5.4 <i>Infrastructure development</i>	34
5.5 <i>Other policies that apply to the biopharmaceutical industry</i>	34
5.6 <i>Results of the industrial policy</i>	35
6. Intellectual property policy	37
6.1 <i>General legal framework for intellectual property, copyright and industrial property</i>	37

6.2 Industrial property rights in Cuba	37
7. Public health policy	42
7.1 Setting priorities for local production of medicines and other health technologies in Cuba	43
7.2 Pharmaceutical regulation of medicines and other health technologies in Cuba	44
7.3 Results of the public health policy	48
8. Final considerations	56
References	59
Annex: Aspects impacting on the access to health technologies included in the Resolution on the Guidelines of the Economic and Social Policy of the Party and the Revolution	68

Figures

Figure 1 Methodological flowchart	9
Figure 2 Business modalities used by BioCubaFarma	28
Figure 3 Comparison of south–north and south–south cooperation in biotechnology for health in six countries studied	29
Figure 4 Concept map and legal framework for public health and intellectual property.	38
Figure 5 Number of patents issued by the United States Patent and Trademark Office to Cuban entities, by priority year	40
Figure 6 Concept Map: Cuban experience in the local production of medicines, technology transfer, and improvement in access to health care	57

Tables

Table 1 Evolution of general health indicators (selected years)	14
Table 2 Evolution of general education indicators (selected years)	14
Table 3 Cumulative series of university graduates	16
Table 4 Higher education graduates in Cuba, 2009–13	17
Table 5 Numbers of medical education centres in Cuba, 2013.	17
Table 6 BioCubaFarma human resources by scientific and teaching category.	18
Table 7 Scientific production centres at the core of BioCubaFarma.	21
Table 8 Cuban neurotechnology timeline.	25
Table 9 Technology transfer from Cuba to other countries	29
Table 10 Summary of characteristics of technology transfers made by Cuba	31
Table 11 BioCubaFarma companies and representative offices abroad	31
Table 12 Pharmaceutical trade balance 1995–2010 (US\$ thousands)	35
Table 13 Export revenues of the Cuban biopharmaceutical industry	36
Table 14 Rights granted and requested by BioCubaFarma, December 2013.	39
Table 15 Cuban inventions awarded the WIPO Gold	41
Table 16 Contribution of national drug production by therapeutic category, Cuba 2013.	49
Table 17 Cuban immunoassay technology in the national public health system	52
Table 18 Products for human use developed by CIGB and approved for sale	54
Table 19 Indicators associated with antiretroviral therapy	55

Boxes

Box 1 Principles of the Cuban public health system	42
Box 2 National Drug Programme	43

Preface

This case study was led by Beatriz M. García, MSc (chemist), independent consultant on intellectual property, technology intelligence and project management. Emma Uramís (microbiologist) and Esther M. Fajardo MSc (biologist), independent consultants on the biopharmaceutical industry, including regulatory requirements and vaccines, contributed to its drafting. The work was supervised by Dr José Luis Di Fabio, Pan American Health Organization (PAHO) and World Health Organization (WHO) representative in Cuba. The study was conducted at the request of Dr Zafar Mirza of WHO.

Acknowledgements

The authors wish to thank the representatives of the Ministry of Public Health (MINSAP) and the Ministry of Higher Education of Cuba, and the directors and officers of the BioCubaFarma higher business management organization, who provided information for this case study. We would also like to acknowledge those who reviewed this document, especially Dr Agustín Lage Dávila, Director of the Center for Molecular Immunology, Dr Celeste Sánchez, Adviser, Center for State Control of Drugs, Equipment and Medical Devices, Dr Gustavo Sierra, Director of Science Policy, BioCubaFarma, and Dr Ileana Morales, Director of Science and Technology, MINSAP, who were kind enough to send us their comments and suggestions.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27435

